CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 15, 2013--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
today announced that President/Chief Executive Officer, Robert
Forrester, Chief Medical Officer, Dr. Joanna Horobin, and Head of
Research, Dr. Jonathan Pachter, will participate in upcoming life
science panel discussions later this month. The details of the events
are below.
Women who Inspire
Date:
Wednesday, October 16, 2013 (7:30 – 9:00 a.m.)
Location:
Biogen Idec, 14 Cambridge Center, Building 6, Cambridge, MA
Panelists:
Dr. Joanna Horobin, Chief Medical Officer, Verastem, Inc., Dr.
Rosana Kapeller, Chief Scientific Officer, Nimbus Discovery, Daphne
Zohar, Chief Executive Officer, Pure Tech Ventures
Moderator:
Karen Weintraub, health and science journalist, author and former Boston
Globe editor.
Sponsor: Northeastern’s Alumni Association
The Next 25 Years of Boston Biotech
Date:
Tuesday, October 29, 2013 (7:45 - 9:15 a.m.)
Location: Ritz
Carlton Hotel, Boston, MA
Panelists: Robert Forrester,
President/CEO, Verastem, Inc., Dr. Michelle Dipp, CEO & Co-founder,
OvaScience, Katrine Bosley, Entrepreneur-in-Residence, Broad Institute
of MIT & Harvard
Moderator: Rob Weisman, Reporter, The
Boston Globe
Sponsor: Boston Chamber of Commerce
2013 Chabner Colloquium, Collaboration in Cancer
Drug Trials; Stem Cells and Circulating Tumor Cells
Date:
Tuesday, October 29, 2013 (10:15 – 11:00 a.m.)
Location:
Starr Center, Schepens Eye Institute, Boston, MA
Panelists: Dr.
Jonathan Pachter, Head of Research, Verastem, Inc.
Moderator:
Dr. David Fisher, Mass General Hospital
Sponsor: Society for
Translational Oncology and the Massachusetts General Hospital
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is
discovering and developing drugs to treat cancer by the targeted killing
of cancer stem cells. Cancer stem cells are an underlying cause of tumor
recurrence and metastasis. Verastem is developing small molecule
inhibitors of signaling pathways that are critical to cancer stem cell
survival and proliferation: FAK, PI3K/mTOR and Wnt. For more
information, please visit www.verastem.com.
Forward-looking statements:
Any statements in this press
release about future expectations, plans and prospects for the Company
constitute forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements. The
Company anticipates that subsequent events and developments will cause
the Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so.
Source: Verastem, Inc.
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com
